Quantum Biopharma (QNTM) Cash & Equivalents (2018 - 2026)

Quantum Biopharma (QNTM) has 9 years of Cash & Equivalents data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 23.41% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.3 million (up 23.41% YoY), and the FY2025 full-year result was $1.9 million, down 68.22% from the prior year.
• Cash & Equivalents grew to $4.3 million in Q1 2026, from $1.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $31.6 million in Q2 2022 to a low of $445944.0 in Q3 2025.
• A 5-year average of $9.6 million and a median of $4.3 million in 2026 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 85.71% in 2025 and climbed 23.41% in 2026, its largest moves.
• Tracing QNTM's Cash & Equivalents over 5 years: stood at $17.0 million in 2022, then slumped by 78.6% to $3.6 million in 2023, then surged by 65.0% to $6.0 million in 2024, then tumbled by 68.22% to $1.9 million in 2025, then surged by 127.88% to $4.3 million in 2026.
• Business Quant data shows QNTM's Cash & Equivalents at $4.3 million in Q1 2026, $1.9 million in Q4 2025, and $445944.0 in Q3 2025.